Table 1 |. Six loci from the genome-wide and candidate-based search for association with Rapid3 or CKDi25.

Shown are (A) the significant lead variants from the GWAS (genome-wide significance, P-value<5.0×10⁻⁸) and (B) the significant variants from the candidate-based approach inquiring the 265 variants reported for cross-sectional eGFRcrea¹⁷ (Bonferroni-corrected significance, P-value<0.05/265≈1.89×10⁻⁴).

						Rapid3		CKDi25
RSID	Chr:Position	Identifying analysis	Locus name	EA/OA	EAF	OR	P	OR	P	Locus/signal no.	Reference variant (R2)
(A) Genome-wide search (genome-wide significance, P-value<5×10−8)
rs13329952	16:20,366,507	Rapid3	[UMOD-PDILT]	t/c	0.79	1.101	2.35×10−17	1.203	6.22×10−30	1.1
rs12922822	16:20,367,645	CKDi25		c/t	0.81	1.103	1.13×10−16	1.224	3.51×10−33		rs13329952 (0.91)
rs77924615	16:20,392,332	CKDi25 2nd (a)	[UMOD-PDILT]	g/a	0.79	1.023	0.0384	1.112	2.98×10−10	1.2
rs77593734	15:54,002,606	CKDi25	[WDR72]	t/c	0.72	1.040	1.18×10−4	1.102	1.42×10−11	2
rs56012466	7:151,406,788	CKDi25	[PRKAG2]	a/g	0.27	1.041	1.12×10−4	1.090	1.53×10−9	3
rs141809766	9:35,937,931	Rapid3	[OR2S2]	g/a	0.02	1.222	5.94×10−9	1.065	0.252	4
(B) Candidate approach based on 265 (c) reported lead variants from cross-sectional eGFRcrea GWAS (significance P-value<0.05/265≈1.89×10−4)
rs34882080 (b)	16:20,361,441	CKDi25; Rapid3	[UMOD-PDILT]	a/g	0.81	1.100	1.11×10−15	1.216	2.98×10−31	1.1	rs12922822 (0.99)
rs77924615	16:20,392,332	CKDi25; Rapid3	[UMOD-PDILT]	g/a	0.79	1.084	1.40×10−10	1.256	1.29×10−28	1.2
rs690428	15:53,950,578	CKDi25	[WDR72]	a/c	0.71	1.027	0.0117	1.078	1.46×10−5	2	rs77593734 (0.42)
rs10254101	7:151,415,536	CKDi25	[PRKAG2]	t/c	0.28	1.037	5.35×10−4	1.087	4.32×10−9	3	rs56012466 (0.84)
rs80282103	10:899,071	CKDi25	[LARP4B]	t/a	0.08	1.027	0.100	1.103	2.97×10−5	5
rs1145077	15:45,683,795	Rapid3	[GATM]	t/g	0.40	1.038	7.94×10−5	1.042	1.93×10−3	6	rs1145089 (0.99)

RSID=Variant identifier on GRCh37, Chr:Position=Chromosome and Position on GRCh37, Identifying analysis=Trait und analysis for which the variant was identified with significant association (“2^nd“ indicating the second signal analysis), Locus name=Nearest gene, stated in brackets to distinguish from gene and protein names, EA=Effect allele: cross-sectional eGFRcrea-lowering allele, OA=Other allele, EAF=Effect allele frequency, OR=Odds ratio, P=Genomic control corrected association P-value, Locus/ signal no.=Locus number and signal number highlighting that four of the six candidate-based identified variants capture the same locus/signal as the GWAS, Reference variant (R²)=Variant to which the identified variant is compared to in terms of correlation (spearman correlation coefficient squared). (a) Stated are OR and P-value for Rapid3 and CKDi25 adjusted for the lead variant of the respective primary GWAS (rs13329952 or rs12922822). Unadjusted OR=1.08 and 1.26 (P-value=1.40×10⁻¹⁰ and 1.29×10⁻²⁸) for Rapid3 and CKDi25, respectively; (b) Lead variant of 2nd signal in [UMOD-PDILT] from cross-sectional eGFRcrea analysis in European ancestry¹⁷; (c) 264 reported lead variants plus the lead variant of the 2^nd signal in [UMOD-PDILT] from cross-sectional eGFRcrea GWAS¹⁷.